JMP Securities Reiterates Market Perform Rating on Incyte (INCY) Aug 19, 2024 05:58AM
JMP Securities Downgrades Incyte (INCY) to Market Perform, 'A Material Acquisition is Necessary' Feb 14, 2024 03:42AM
Incyte (INCY) PT Raised to $124 at JMP Securities, Following Drug Trial Results Jul 23, 2020 02:20PM
Incyte Investor Conference Update Jun 17, 2020 08:00AM
Incyte to Present at Upcoming Investor Conferences Jun 3, 2020 08:00AM


Jan 3, 2020 05:13AM Incyte (INCY) PT Lowered to $99 at JMP Securities
Sep 30, 2019 04:36AM Incyte (INCY) PT Raised to $110 at JMP Securities
Sep 5, 2019 03:40AM JMP Securities Transfers Coverage on Incyte (INCY), Upgrades to Market Outperform
Aug 1, 2018 05:24AM JMP Securities Downgrades Incyte (INCY) to Market Perform Citing Valuation
Jul 19, 2018 05:49AM Incyte (INCY) PT Raised to $84 at JMP Securities
May 2, 2018 04:28AM UPDATE: JMP Securities Reinstates Incyte (INCY) at Market Outperform, 'Near-term Catalyst in GVHD to Provide a Boost to Valuation'
Feb 26, 2014 11:21AM Notable Analyst Rating Changes 02/26: (LNKD) (RRC) (ARIA) Upgraded; (PSA) (NIHD) (HUM) Downgraded